Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
My American Story
Roads, Travel and Traffic
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Jobs
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
My American Story
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Jobs
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Foghorn Therapeutics Inc. - Common Stock
(NQ:
FHTX
)
4.240
+0.060 (+1.44%)
Streaming Delayed Price
Updated: 12:26 PM EDT, Jun 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
80,495
Open
4.130
Bid (Size)
4.230 (400)
Ask (Size)
4.260 (400)
Prev. Close
4.180
Today's Range
4.110 - 4.345
52wk Range
3.270 - 6.950
Shares Outstanding
36,936,886
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Targets Next Wave of DNA Damage Response Cancer Therapies
June 22, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
June 22, 2026
Via
Investor Brand Network
Performance
YTD
-18.3%
-18.3%
1 Month
-3.0%
-3.0%
3 Month
-16.7%
-16.7%
6 Month
-26.6%
-26.6%
1 Year
-13.3%
-13.3%
More News
Read More
Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
June 05, 2026
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May
May 12, 2026
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
May 07, 2026
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
April 21, 2026
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
April 09, 2026
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
March 11, 2026
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
February 24, 2026
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
February 23, 2026
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
February 03, 2026
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
January 13, 2026
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
January 09, 2026
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
November 25, 2025
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
This Aardvark Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday
↗
November 07, 2025
Via
Benzinga
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
November 05, 2025
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
These stocks are gapping in today's session
↗
November 04, 2025
Via
Chartmill
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
November 03, 2025
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs
October 30, 2025
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
October 16, 2025
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
August 27, 2025
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
↗
August 11, 2025
Via
Benzinga
Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update
August 05, 2025
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
May 22, 2025
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
May 14, 2025
From
Foghorn Therapeutics, Inc.
Via
GlobeNewswire
Frequently Asked Questions
Is Foghorn Therapeutics Inc. - Common Stock publicly traded?
Yes, Foghorn Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Foghorn Therapeutics Inc. - Common Stock trade on?
Foghorn Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Foghorn Therapeutics Inc. - Common Stock?
The ticker symbol for Foghorn Therapeutics Inc. - Common Stock is FHTX on the Nasdaq Stock Market
What is the current price of Foghorn Therapeutics Inc. - Common Stock?
The current price of Foghorn Therapeutics Inc. - Common Stock is 4.240
When was Foghorn Therapeutics Inc. - Common Stock last traded?
The last trade of Foghorn Therapeutics Inc. - Common Stock was at 06/23/26 12:26 PM ET
What is the market capitalization of Foghorn Therapeutics Inc. - Common Stock?
The market capitalization of Foghorn Therapeutics Inc. - Common Stock is 156.61M
How many shares of Foghorn Therapeutics Inc. - Common Stock are outstanding?
Foghorn Therapeutics Inc. - Common Stock has 157M shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today